Compare Merck & Co., Inc. (MRK) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs US Bancorp — how do they compare? Merck & Co., Inc. trades at $125.98 (market cap $307.25B), while US Bancorp trades at $63.14 (market cap $98.36B). The key difference: Merck & Co., Inc. is far larger — about 3.1× US Bancorp's market cap, and US Bancorp pays the higher dividend (3.29%). Which is the better fit depends on your goals.
| MRK | USB | |
|---|---|---|
Market Cap | $307.25B | $98.36B |
Sector | Health | Financials |
52-Week High | $129.52 | $64.01 |
52-Week Low | $77.60 | $43.94 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
U.S. Bancorp (USB) trades at $63.71, up 0.9% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a P/E of 12.6, and a net income margin of 27.61%. Recent Q2 2026 results highlighted record revenue driven by loan growth and fee income, with the company raising its full-year revenue outlook to 7%-9% growth. Analyst consensus is a Buy with a $70.17 price target, indicating 10% upside potential.
The outlook for USB is positive, supported by earnings momentum, dividend yield near 3%, and institutional optimism. Key risks include rising debt-to-asset ratios, potential credit quality deterioration, and macroeconomic sensitivity. Investors should weigh the stock's attractive valuation against sector-wide interest rate and regulatory uncertainties for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
